The mechanism by which pharmacologic administration of the hormone FGF21 increases energy expenditure to cause weight loss in obese animals is unknown. Here we report that FGF21 acts centrally to exert its effects on energy expenditure and body weight in obese mice. Using tissue-specific knockout mice, we show that bKlotho, the obligate coreceptor for FGF21, is required in the nervous system for these effects. FGF21 stimulates sympathetic nerve activity to brown adipose tissue through a mechanism that depends on the neuropeptide corticotropin-releasing factor. Our findings provide an unexpected mechanistic explanation for the strong pharmacologic effects of FGF21 on energy expenditure and weight loss in obese animals.
INTRODUCTION
FGF21 is a hormone expressed in liver, where it is induced by states of nutrient stress, including starvation and ketogenic or high-carbohydrate diets, and the fibrate drugs. FGF21 is also expressed in white adipose tissue (WAT), where it is induced by fasting/refeeding regimens and the thiazolidinedione drugs, and in brown adipose tissue (BAT), where it is induced by cold (reviewed in Potthoff et al., 2012) . In rodent models of obesity, FGF21 administration caused weight loss by increasing energy expenditure and improved insulin sensitivity and lipid parameters (Coskun et al., 2008; Kharitonenkov et al., 2005; Xu et al., 2009a Xu et al., , 2009b . Similar metabolic effects were seen in diabetic rhesus monkeys and patients with type 2 diabetes (Gaich et al., 2013; Kharitonenkov et al., 2007; Vé niant et al., 2012b) .
FGF21 acts through a cell surface receptor comprised of an FGF receptor (FGFR), with FGFR1c the preferred isoform, in complex with bKlotho (reviewed in Potthoff et al., 2012) . While the FGFRs are broadly expressed, bKlotho is expressed in a more limited set of tissues, including WAT, BAT, and liver (Fon Tacer et al., 2010) . FGF21 mediates its pharmacologic effects on body weight and insulin sensitivity in part through WAT and BAT (Adams et al., 2012; Ding et al., 2012; Vé niant et al., 2012a; Wu et al., 2011) , where it induces uncoupling protein-1 (Ucp1) and uncoupled respiration (Fisher et al., 2012; Hondares et al., 2010) and the hormone adiponectin Lin et al., 2013) . FGF21 also acts on the nervous system. FGF21 is not expressed in the CNS (Fon Tacer et al., 2010) but crosses the blood-brain barrier (Hsuchou et al., 2007) and is present in human cerebrospinal fluid (Tan et al., 2011). Intracerebroventricular (i.c.v.) injection of FGF21 increased metabolic rate and insulin sensitivity in rats (Sarruf et al., 2010) . Within the nervous system, bKlotho is expressed in the suprachiasmatic nucleus (SCN) in the hypothalamus. It is also expressed in the area postrema, nucleus of the solitary tract, and nodose ganglia, which are discrete anatomical nuclei that together comprise the dorsal-vagal complex (DVC) . Using lean mice specifically lacking bKlotho in the hypothalamus and/or the hindbrain, we showed that bKlotho in the hypothalamus is required for FGF21 to increase circulating ketone body and glucocorticoid concentrations, to suppress growth and female reproduction, and to modulate circadian behavior Owen et al., 2013) . However, since these studies were all done in lean mice, they did not address whether the effects of FGF21 on energy expenditure require that it act on the nervous system. In this paper, we examine the contribution of the nervous system to the pharmacologic actions of FGF21 in the context of diet-induced obesity (DIO).
RESULTS AND DISCUSSION
FGF21 Acts Centrally to Induce Energy Expenditure Fgf21-transgenic (Tg) mice are resistant to weight gain (Ding et al., 2012; Kharitonenkov et al., 2005) . To determine whether this effect involves FGF21 acting in the brain, we crossed Klb Camk2a mice, in which the bKlotho gene (Klb) is disrupted in both the hypothalamus (including the SCN) and DVC, but not in adipose tissue and liver /Tg mice ( Figure 1A ). When fed a high-fat diet (HFD), Klb fl/fl /Tg mice gained less weight than Klb fl/fl and Klb Camk2a mice ( Figure 1B ). These effects of FGF21 overexpression were lost in the Klb Camk2a /Tg mice ( Figure 1B ). HFD-fed Klb fl/fl /Tg mice had a reduced percentage of fat mass and plasma leptin concentrations and increased percentage of lean mass compared to the other three genotypes ( Figure 1C ; Table  S1 , available online). In metabolic cage studies, the Klb fl/fl /Tg mice had significantly increased food consumption and energy expenditure with no change in physical activity ( Figures 1D  and 1E ). This significant effect of FGF21 on energy expenditure was not observed in the same mice fed a regular chow diet ( Figure 1E ), suggesting that oxidative substrate was limiting.
Together, these data demonstrate that in the context of nutritional surfeit, FGF21 acts on the nervous system to stimulate energy expenditure. (Table S1 ). Likewise, hepatic cholesterol and triglyceride concentrations were significantly lower in Klb fl/fl /Tg mice than in the other genotypes (Table S1 ). Data are shown as the mean ± SEM. n = 8-13/group (A-C); n = 6/group (D and E). *p < 0.05 compared to control. , mice (Figures 2A-2D ). There were no differences among genotypes in Fgfr1c expression. In BAT, Ucp1, deiodinase 2 (Dio2), and elongation of very long chain fatty acids like 3 (Elovl3) were elevated in Klb fl/fl /Tg compared to Klb fl/fl mice, consistent with increased thermogenesis ( Figure 2A) . Interestingly, bone morphogenic protein 8b (Bmp8b), which is induced in BAT in response to cold or HFD feeding and sensitizes BAT to the thermogenic actions of norepinephrine (Whittle et al., 2012) demonstrating that bKlotho in the nervous system is important for FGF21 to exert many of its pharmacologic effects on gene expression in adipose tissue. Since FGF21 also acts directly on adipocytes to induce Ucp1 and other genes (Fisher et al., 2012; Hondares et al., 2010) , their maximal induction likely involves cooperative effects of FGF21 on both adipose tissue and the nervous system. In liver, fatty acid synthase (Fasn), Scd1, Acaca, Cd36, and Elovl6 were decreased in Klb fl/fl /Tg compared to Klb fl/fl mice ( Figure 2D ). These inhibitory effects of FGF21 were also absent in Klb Camk2a /Tg mice ( Figure 2D) . A recent study showed that the effects of FGF21 on reducing triglyceride and cholesterol concentrations were lost in liver-specific insulin receptor knockout mice (Emanuelli et al., 2014) . Similarly, the loss of FGF21 action in liver of Klb Camk2a /Tg mice may be secondary to the loss of its insulin-lowering action (Table  S1 ). Expression of dual specificity phosphatase 4 (Dusp4), which inhibits ERK1/2, was increased in Klb fl/fl /Tg mice compared to Klb fl/fl mice in all three adipose tissue depots, but not liver (Figures 2A-2D ). Dusp4 was still increased in Klb
Camk2a
/Tg compared to Klb Camk2a mice in BAT and eWAT (Figures 2A and   2C ), reinforcing the notion that FGF21 can also act directly on adipose tissue.
FGF21 Acts on the Hypothalamus
To assess the relative contribution of bKlotho in the DVC versus the hypothalamus to the metabolic actions of FGF21, we crossed Fgf21-Tg mice with Klb Phox2b mice, in which Klb is disrupted in the DVC but not the hypothalamus Figure S1B ). However, the significance of Ucp1 induction in scWAT was lost in the Klb Phox2b /Tg mice ( Figure S1B ). Overall, these data support the importance of bKlotho in the hypothalamus and not the DVC for the central actions of FGF21. Since Fgf21-Tg mice are chronically exposed to high levels of FGF21, we examined whether the metabolic effects of shorter-term exposure to recombinant FGF21 in DIO mice also require bKlotho in the nervous system. DIO Klb fl/fl and Klb Camk2a mice were administered FGF21 or vehicle for 2 weeks by osmotic minipump. Plasma FGF21 concentrations were 29 ± 11 ng/ml and 36 ± 13 ng/ml in the Klb fl/fl and Klb Camk2a mice, respectively. As expected, FGF21 decreased body weight, percent body fat, and plasma insulin, glucose, cholesterol, and leptin concentrations in DIO Klb fl/fl mice ( Figure 3A ). All of these effects of FGF21 were absent in the Klb Camk2a mice (Figure 3A) . FGF21 administration also increased Ucp1 expression in BAT and scWAT in Klb fl/fl , but not Klb Camk2a , mice ( Figure 3B ).
Overall, the pattern of gene expression in BAT, scWAT, eWAT, and liver of Klb fl/fl and Klb Camk2a mice in response to recombinant FGF21 was similar to that seen with the FGF21 transgene, with nearly all of the effects of FGF21 lost in the Klb Camk2a background ( Figure S2 ). Thus, bKlotho in the nervous system is required for the pharmacologic actions of FGF21 in DIO mice.
FGF21 Induces Sympathetic Nerve Activity
Since BAT-mediated energy expenditure is regulated by the sympathetic nervous system, we used multifiber sympathetic nerve recording to directly measure the effect of FGF21 on sympathetic nerve activity (SNA) subserving BAT in mice. Injection of FGF21 i.c.v. increased BAT SNA in a time-and dose-dependent manner ( Figures 4A and 4B ). SNA was induced approximately 30 min after FGF21 administration and continued to increase over the 4 hr experiment. This effect was blocked by i.c.v. pretreatment with PD173074 ( Figure  4B ), which inhibits the tyrosine kinase activities of FGFR1, FGFR2, and FGFR3 (Kunii et al., 2008; Mohammadi et al., 1998) . Intravenous (i.v.) injection of FGF21 also increased BAT SNA, which was inhibited by i.c.v. pretreatment with PD173074 ( Figure 4C ). The onset of SNA induction was slower after i.v. injection compared to i.c.v. injection, as expected, since FGF21 must cross the blood-brain barrier. The effect of FGF21 on SNA when administered peripherally was 
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Camk2a mice ( Figure 4D ). The residual effect of FGF21 on BAT SNA in the Klb Camk2a mice could be due to either incomplete knockout of bKlotho in the nervous system or FGF21 acting via other, unknown mechanisms. Regardless, the data in Figure 1E show that bKlotho in the nervous system is crucial for the effect of FGF21 on energy expenditure.
FGF21 Actions Require Corticotropin-Releasing Factor
We previously showed that corticotropin-releasing factor (Crf) mRNA in hypothalamus and circulating corticosterone concentrations are increased in Fgf21-Tg mice . Likewise, hypothalamic Crf mRNA was elevated 3 hr after intraperitoneal injection of FGF21, and there was a corresponding increase in plasma adrenocorticotropic hormone (ACTH) ( Figure 4E ). While ACTH concentrations were increased under these acute FGF21 treatment conditions, they were reduced after administration of FGF21 for 2 weeks and in Fgf21-Tg mice , suggesting that chronic FGF21 exposure sensitizes the adrenal to ACTH. Indeed, there is evidence that the autonomic nervous system can modulate the sensitivity of the adrenal to ACTH (Kalsbeek et al., 2010) . Since i.c.v. injection of CRF stimulates sympathetic outflow to BAT and thermogenesis in rats (Arase et al., 1988; Cerri and Morrison, 2006; LeFeuvre et al., 1987) , we tested whether CRF contributes to the effects of FGF21 on BAT. Notably, i.c.v. injection of the CRF receptor antagonist, a-helical CRF(9-41) (Rivier et al., 1986) , which inhibits both the CRF1 and CRF2 receptor subtypes, completely blocked the effect of FGF21 on SNA in BAT ( Figure 4F ). This finding that FGF21 action involves downstream effects on CRF likely explains the relatively slow onset of SNA in BAT in response to FGF21. In the hypothalamus, bKlotho is most highly expressed in the SCN, whereas CRF is primarily localized in the paraventricular nucleus (PVN). Since the SCN is known to act on the PVN to regulate the circadian pattern of CRF and corticosterone release (Kalsbeek et al., 2010) , FGF21 may mediate its effects on CRF indirectly via the SCN. However, the precise neuroanatomical relationship between bKlotho and CRF remains to be determined. Nevertheless, our findings suggest that FGF21 regulates both BAT SNA and corticosterone levels via its effects on CRF.
In summary, we demonstrate that FGF21 acts centrally to stimulate sympathetic outflow, energy expenditure, and weight loss in DIO mice. We previously showed that the acute effects of FGF21 on whole-body insulin sensitivity and glucose uptake in BAT were lost in HFD-fed mice lacking bKlotho in adipose tissue (Ding et al., 2012) . How do we reconcile these findings? In vivo, the thermogenic effects of UCP1 require both norepinephrine and oxidative substrate (Nedergaard et al., 2005) . For example, while PPARg agonists efficiently stimulate Ucp1 expression and lipid accumulation in both brown and white adipocytes, they do not increase thermogenesis. However, they potentiate the thermogenic actions of b-adrenergic receptor agonists (Foellmi-Adams et al., 1996; Sell et al., 2004; Thurlby et al., 1987) . We suggest that FGF21 works similarly to this combination of PPARg and b-adrenergic receptor agonists through a 2-fold mechanism ( Figure 4G ). First, FGF21 acts on the nervous system to stimulate sympathetic outflow to BAT, which induces Ucp1 and lipolysis (Cannon and Nedergaard, 2004) . FGF21 also promotes the browning of scWAT (Fisher et al., 2012) , an effect that in vivo involves bKlotho in the nervous system. Second, FGF21 acts directly on BAT and scWAT to increase glucose uptake and substrate mobilization. Accordingly, we find that energy expenditure is markedly upregulated in lean Fgf21-Tg mice when they are switched to the HFD and additional substrate is made available for oxidation ( Figure 1E ). Thus, FGF21 regulates both the mobilization and uncoupled oxidation of substrate in BAT and browned WAT. /FGF21, 36 ± 1.3. Data are shown as the mean ± SEM. n = 5-6/group. *p < 0.05 compared to vehicle.
EXPERIMENTAL PROCEDURES
Mouse Studies Mouse strains have been described and are on mixed C57BL6J;129/Sv backgrounds Owen et al., 2013) . Age-matched 3-to 7-monthold male littermates were used for all experiments and were fed either a standard chow (Harlan Teklad, TD.2916) or a high-fat diet containing 60% fat (Research Diets, D12492i) . For the minipump experiments, mice were maintained on the high-fat diet for 12 weeks prior to initiating the experiment. Housing rooms were maintained between 22
C and 23 C. Metabolic cage studies were performed at 21 C-22 C. Indirect calorimetry using LabMaster (G) Model for the effects of FGF21 on energy expenditure. FGF21 acts on the hypothalamus to induce corticotropin-releasing factor (CRF) and to stimulate sympathetic nerve activity (SNA), which in turn induces uncoupling protein-1 (UCP1) and lipolysis in brown adipose tissue (BAT). FGF21 also acts directly on BAT to stimulate glucose uptake and to mobilize oxidative substrate. These dual effects induce efficient energy expenditure. The model is based on this study and previous literature (Cannon and Nedergaard, 2004; Ding et al., 2012) . metabolic cages (TSE Systems) was used to determine energy expenditure per gram of lean body mass. Energy expenditure was calculated as a function of O 2 consumption and CO 2 production according the following formula: energy expenditure (kcal/hr) = ((3.941 3 vO 2 (ml/hr)) + (1.106 3 vCO 2 (ml/hr)))/1,000. Body composition was measured using an EchoMRI-100 Body Composition Analyzer. All experiments were approved by the Institutional Animal Care and Research Advisory Committee of the University of Texas Southwestern Medical Center or the University of Iowa.
Materials
Recombinant human FGF21 was from Novo Nordisk. Subcutaneous osmotic pumps were from ALZET. PD173074 was from Sigma. a-helical CRF(9-41) was from Phoenix Pharmaceuticals. The following kits were used to measure Cell Metabolism FGF21 Activates the Sympathetic Nervous System metabolic parameters: glucose (Wako Chemicals), triglycerides (Wako Chemicals), cholesterol (Fisher Scientific) , insulin (Crystal Chem), leptin (Linco), and adrenocorticotropic hormone. Liver triglyceride and cholesterol levels were measured as described (Zhang et al., 2012) .
Real-Time Quantitative PCR Analyses
Total RNA was extracted from liver using Stat 60 reagent (IsoTex Diagnostics). For adipose tissue, RNeasy lipid tissue mini kits (QIAGEN) were used. RNA (1-2 mg) from each sample was then used to generate cDNA (Invitrogen). qPCR was performed using SYBR green as described (Bookout et al., 2006) .
Sympathetic Nerve Activity Measurements
Measurement of sympathetic nerve activity to BAT was performed as described (Harlan et al., 2011; Lockie et al., 2012; Morgan and Rahmouni, 2010) . Following the establishment of baseline values, mice were pretreated for 10 min with either vehicle (10 mM Na 2 HPO 4 , 2% [w/v] glycerol [pH 7.6]), PD173074, or a-helical CRF(9-41) administered i.c.v. followed by i.c.v. or i.v. (jugular vein infusion) administration of vehicle (10 mM Na 2 HPO 4 , 2% [w/v] glycerol [pH 7.6]) or recombinant FGF21. SNA was recorded for an additional 4 hr. All i.c.v. injection volumes were 2 ml. The dose of PD173074 used (25 mg), which had no effect on SNA on its own ( Figure 4B ), was based on a previous publication in which PD173074 inhibited FGF19 action (Morton et al., 2013) . The dose of a-helical CRF(9-41) (6 mg) was based on a previous publication in which this CRF antagonist blocked SNA activity in rats (Correia et al., 2001 ).
Statistical Analyses
Statistical analyses were performed by two-way ANOVA with post hoc correction (GraphPad Prism) unless indicated otherwise. Data are presented as the mean ± SEM; p < 0.05 was considered significant. 
